Eikon Therapeutics Inc. is a clinical-stage biotechnology company dedicated to revolutionizing drug discovery through the application of super-resolution microscopy and advanced engineering. Founded by a team including Nobel laureate Eric Betzig, the company utilizes a proprietary platform that tracks the movement of individual protein molecules in living cells. This 'Single-Molecule Tracking' (SMT) technology allows researchers to observe the dynamic behavior of proteins in real-time, providing unique insights into disease mechanisms and potential therapeutic targets that were previously inaccessible. Eikon's approach integrates high-throughput imaging, machine learning, and sophisticated software to analyze massive datasets, enabling the identification of novel drug candidates with high precision. The company's pipeline targets a range of therapeutic areas, including oncology, immunology, and neurodegeneration. By combining physics, biology, and engineering, Eikon aims to accelerate the drug discovery process and bring life-changing medicines to patients with high unmet medical needs.